Targets › NK1R
1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Dec 2027.
Receptor for the tachykinin substance P, also able to bind and respond to tachynins neurokinin A/substance K and neurokinin B/neuromedin-K. The rank order of affinity of this receptor to tachykinins is: substance P > neurokinin A/substance K > neurokinin B/neuromedin-K. Substance P binding to its receptor triggers G protein-coupled receptor signaling via activation of phosphatidylinositol hydrolysis by phospholipase…. (UniProt, P25103)
Open in Phaseline: the race on NK1R, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chinese University of Hong Kong | Netupitant Neurokinin-1 (NK1) receptor antagonist | NK1R | Phase 2 | Breast Cancer | Dec 2027 |
Breast Cancer (1)
small molecule (1)
Chinese University of Hong Kong (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.